Dr. Traina on Treatment Considerations for HER2+ Breast Cancer

Video

In Partnership With:

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, on considerations for the treatment of patients with HER2-positive breast cancer.

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, on considerations for the treatment of patients with HER2-positive breast cancer.

With the FDA approval of neratinib (Nerlynx) in July of 2017, clinicians began to consider its role in the treatment paradigm of HER2-positive breast cancer. With the success of pertuzumab (Perjeta), and the established role of trastuzumab (Herceptin), some clinicians have found it difficult to decide where to place neratinib in the sequence of treatment for these patients.

Traina says that she favors using pertuzumab in patients with tumors larger that 2 cm in the setting of node negative or positive disease. She also incorporates neoadjuvant therapy with anthracycline taxane-based trastuzumab and pertuzumab, and then following surgery, administering trastuzumab and pertuzumab for a full year. For tumors that are smaller than 2 cm, Traina supports the idea of de-escalation. Neratinib, she says, is difficult to place, but it could be an option for patients that are extremely high risk after prior treatment.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,